Katerina Deike-Hofmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Katerina Deike-Hofmann has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
Alexander Radbruch
German Center for Neurodegenerative Diseases (DZNE), Helmholtz Association of German Research Centers
5 shared publications- Alexander Radbruch
Clinic of Neuroradiology, University Hospital Bonn, Bonn, Germany
5 shared publications Heinz-Peter Schlemmer
Department of Radiology, German Cancer Research Center, DKFZ, Heidelberg, Germany
4 shared publications- Thomas Pinetz
Medical University of Vienna
3 shared publications Alexander Effland
Institute of Applied Mathematics, Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn, Germany
2 shared publications- Alexander Effland
Institute for Applied Mathematics, University of Bonn, Bonn, Germany
2 shared publications
Latest Publications
- 1 November 2024
- Published by Radiological Society of North America (RSNA) in Radiology: Artificial Intelligence
- Vol. 6 (6) , e230514
Addressing the Generalizability of AI in Radiology Using a Novel Data Augmentation Framework with Synthetic Patient Image Data: Proof-of-Concept and External Validation for Classification Tasks in Multiple Sclerosis
Generative adversarial network–based synthetic data augmentation during model training substantially improved performance of artificial intelligence models when applied to external MRI data and may be extended to a variety of clinical tasks to reduce domain shift on unseen data.
- 1 November 2024
- Published by Radiological Society of North America (RSNA) in Radiology: Artificial Intelligence
- Vol. 6 (6) , e230514
Addressing the Generalizability of AI in Radiology Using a Novel Data Augmentation Framework with Synthetic Patient Image Data: Proof-of-Concept and External Validation for Classification Tasks in Multiple Sclerosis
Generative adversarial network–based synthetic data augmentation during model training substantially improved performance of artificial intelligence models when applied to external MRI data and may be extended to a variety of clinical tasks to reduce domain shift on unseen data.
- 23 April 2024
- Published by Wolters Kluwer Health in Investigative Radiology
- Vol. 59 (9) , 667-676
Machine Learning–Based Perivascular Space Volumetry in Alzheimer Disease
Objectives: Impaired perivascular clearance has been suggested as a contributing factor to the pathogenesis of Alzheimer disease (AD). However, it remains unresolved when the anatomy of the perivascular space (PVS) is altered during AD progression. Therefore, this study investigates the association between PVS volume and AD progression in cognitively unimpaired (CU) individuals, both with and without subjective cognitive decline (SCD), and in those clinically diagnosed with mild cognitive impairment (MCI) or mild AD. Materials and Methods: A convolutional neural network was trained using manually corrected, filter-based segmentations (n = 1000) to automatically segment the PVS in the centrum semiovale from interpolated, coronal T2-weighted magnetic resonance imaging scans (n = 894). These scans were sourced from the national German Center for Neurodegenerative Diseases Longitudinal Cognitive Impairment and Dementia Study. Convolutional neural network–based segmentations and those performed by a human rater were compared in terms of segmentation volume, identified PVS clusters, as well as Dice score. The comparison revealed good segmentation quality (Pearson correlation coefficient r = 0.70 with P < 0.0001 for PVS volume, detection rate in cluster analysis = 84.3%, and Dice score = 59.0%). Subsequent multivariate linear regression analysis, adjusted for participants' age, was performed to correlate PVS volume with clinical diagnoses, disease progression, cerebrospinal fluid biomarkers, lifestyle factors, and cognitive function. Cognitive function was assessed using the Mini-Mental State Examination, the Comprehensive Neuropsychological Test Battery, and the Cognitive Subscale of the 13-Item Alzheimer’s Disease Assessment Scale. Results: Multivariate analysis, adjusted for age, revealed that participants with AD and MCI, but not those with SCD, had significantly higher PVS volumes compared with CU participants without SCD (P = 0.001 for each group). Furthermore, CU participants who developed incident MCI within 4.5 years after the baseline assessment showed significantly higher PVS volumes at baseline compared with those who did not progress to MCI (P = 0.03). Cognitive function was negatively correlated with PVS volume across all participant groups (P ≤ 0.005 for each). No significant correlation was found between PVS volume and any of the following parameters: cerebrospinal fluid biomarkers, sleep quality, body mass index, nicotine consumption, or alcohol abuse. Conclusions: The very early changes of PVS volume may suggest that alterations in PVS function are involved in the pathophysiology of AD. Overall, the volumetric assessment of centrum semiovale PVS represents a very early imaging biomarker for AD.
- 23 April 2024
- Published by Wolters Kluwer Health in Investigative Radiology
- Vol. 59 (9) , 667-676
Machine Learning–Based Perivascular Space Volumetry in Alzheimer Disease
Objectives: Impaired perivascular clearance has been suggested as a contributing factor to the pathogenesis of Alzheimer disease (AD). However, it remains unresolved when the anatomy of the perivascular space (PVS) is altered during AD progression. Therefore, this study investigates the association between PVS volume and AD progression in cognitively unimpaired (CU) individuals, both with and without subjective cognitive decline (SCD), and in those clinically diagnosed with mild cognitive impairment (MCI) or mild AD. Materials and Methods: A convolutional neural network was trained using manually corrected, filter-based segmentations (n = 1000) to automatically segment the PVS in the centrum semiovale from interpolated, coronal T2-weighted magnetic resonance imaging scans (n = 894). These scans were sourced from the national German Center for Neurodegenerative Diseases Longitudinal Cognitive Impairment and Dementia Study. Convolutional neural network–based segmentations and those performed by a human rater were compared in terms of segmentation volume, identified PVS clusters, as well as Dice score. The comparison revealed good segmentation quality (Pearson correlation coefficient r = 0.70 with P < 0.0001 for PVS volume, detection rate in cluster analysis = 84.3%, and Dice score = 59.0%). Subsequent multivariate linear regression analysis, adjusted for participants' age, was performed to correlate PVS volume with clinical diagnoses, disease progression, cerebrospinal fluid biomarkers, lifestyle factors, and cognitive function. Cognitive function was assessed using the Mini-Mental State Examination, the Comprehensive Neuropsychological Test Battery, and the Cognitive Subscale of the 13-Item Alzheimer’s Disease Assessment Scale. Results: Multivariate analysis, adjusted for age, revealed that participants with AD and MCI, but not those with SCD, had significantly higher PVS volumes compared with CU participants without SCD (P = 0.001 for each group). Furthermore, CU participants who developed incident MCI within 4.5 years after the baseline assessment showed significantly higher PVS volumes at baseline compared with those who did not progress to MCI (P = 0.03). Cognitive function was negatively correlated with PVS volume across all participant groups (P ≤ 0.005 for each). No significant correlation was found between PVS volume and any of the following parameters: cerebrospinal fluid biomarkers, sleep quality, body mass index, nicotine consumption, or alcohol abuse. Conclusions: The very early changes of PVS volume may suggest that alterations in PVS function are involved in the pathophysiology of AD. Overall, the volumetric assessment of centrum semiovale PVS represents a very early imaging biomarker for AD.
- Top Cited PapersOpen Access
- 18 April 2024
- Published by Wiley in NMR in Biomedicine
- Vol. 37 (9) , e5159
Human brain clearance imaging: Pathways taken by magnetic resonance imaging contrast agents after administration in cerebrospinal fluid and blood
Over the last decade, it has become evident that cerebrospinal fluid (CSF) plays a pivotal role in brain solute clearance through perivascular pathways and interactions between the brain and meningeal lymphatic vessels. Whereas most of this fundamental knowledge was gained from rodent models, human brain clearance imaging has provided important insights into the human system and highlighted the existence of important interspecies differences. Current gold standard techniques for human brain clearance imaging involve the injection of gadolinium‐based contrast agents and monitoring their distribution and clearance over a period from a few hours up to 2 days. With both intrathecal and intravenous injections being used, which each have their own specific routes of distribution and thus clearance of contrast agent, a clear understanding of the kinetics associated with both approaches, and especially the differences between them, is needed to properly interpret the results. Because it is known that intrathecally injected contrast agent reaches the blood, albeit in small concentrations, and that similarly some of the intravenously injected agent can be detected in CSF, both pathways are connected and will, in theory, reach the same compartments. However, because of clear differences in relative enhancement patterns, both injection approaches will result in varying sensitivities for assessment of different subparts of the brain clearance system. In this opinion review article, the “EU Joint Programme – Neurodegenerative Disease Research (JPND)” consortium on human brain clearance imaging provides an overview of contrast agent pharmacokinetics in vivo following intrathecal and intravenous injections and what typical concentrations and concentration–time curves should be expected. This can be the basis for optimizing and interpreting contrast‐enhanced MRI for brain clearance imaging. Furthermore, this can shed light on how molecules may exchange between blood, brain, and CSF.
- 18 April 2024
- Published by Wiley in NMR in Biomedicine
- Vol. 37 (9) , e5159
Top Cited PapersOpen AccessHuman brain clearance imaging: Pathways taken by magnetic resonance imaging contrast agents after administration in cerebrospinal fluid and blood
Over the last decade, it has become evident that cerebrospinal fluid (CSF) plays a pivotal role in brain solute clearance through perivascular pathways and interactions between the brain and meningeal lymphatic vessels. Whereas most of this fundamental knowledge was gained from rodent models, human brain clearance imaging has provided important insights into the human system and highlighted the existence of important interspecies differences. Current gold standard techniques for human brain clearance imaging involve the injection of gadolinium‐based contrast agents and monitoring their distribution and clearance over a period from a few hours up to 2 days. With both intrathecal and intravenous injections being used, which each have their own specific routes of distribution and thus clearance of contrast agent, a clear understanding of the kinetics associated with both approaches, and especially the differences between them, is needed to properly interpret the results. Because it is known that intrathecally injected contrast agent reaches the blood, albeit in small concentrations, and that similarly some of the intravenously injected agent can be detected in CSF, both pathways are connected and will, in theory, reach the same compartments. However, because of clear differences in relative enhancement patterns, both injection approaches will result in varying sensitivities for assessment of different subparts of the brain clearance system. In this opinion review article, the “EU Joint Programme – Neurodegenerative Disease Research (JPND)” consortium on human brain clearance imaging provides an overview of contrast agent pharmacokinetics in vivo following intrathecal and intravenous injections and what typical concentrations and concentration–time curves should be expected. This can be the basis for optimizing and interpreting contrast‐enhanced MRI for brain clearance imaging. Furthermore, this can shed light on how molecules may exchange between blood, brain, and CSF.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S17)
Intravenously administered gadolinium based contrast agent as a novel approach to longitudinally measure ventricular brain clearance with magnetic resonance imaging in an Alzheimer´s disease model
Background: Amyloidopathy, one pathological hallmark of Alzheimer’s disease (AD), results from dysbalanced amyloid‐β production and clearance. Therefore, disruptions in brain clearance may have a pivotal role as pathogenic drivers. Transgenic mice models of AD may serve to develop and establish minimally invasive in vivo measurement methods to observe brain clearance longitudinally.Method: We used magnetic resonance imaging (MRI) with intravenously administered gadolinium‐based contrast agent (GBCA) on a 7T small animal ultrahighfield MRI scanner to determine brain clearance efficacy. Imaging sessions were performed longitudinally in n = 9 APPswe/PS1dE9 (tg) mice and n = 9 wild type (wt) littermates at 6, 9 and 12 months of age with a scan protocol consisting of a highly T2w Inv. Rec. RARE (FLAIR) sequence. For a subsample of n = 6 wt and n = 6 tg at 9 and 12 months we used an additional T1w RARE sequence for evaluation of parenchymal changes. Both protocols were carried out every 5‐6.5 minutes for a total of 180 minutes. We determined mean voxel values in manually delineated volumes of interest in ventricles (in T2w images) and brain parenchyma (T1w images) using PMOD software.Result: We created intensity‐time‐curves and measured slopes for signal increase and decrease, derived from fitting with a model consisting of an exponential convoluted with another exponential and used to normalize area under the curve (AUC) values (Figure 1A‐C). Repeated measurements ANOVA revealed no differences in normalized AUC values regarding age in both lateral (p = 0.568, F(2, 28) = 0.577), 3rd (p = 0.306, F(1.903, 26.64) = 1.232) and 4th ventricles (p = 0.181, F(1.345, 18.83) = 1.924) and also no differences regarding genotype in both lateral (p = 0.684, F(1,16) = 0.172), 3rd (p = 0.737, F(1,16) = 0.117) and 4th ventricle (p = 0.186, F(1,16) = 1.910). Measurements of parenchymal clearance capacity are still ongoing and first results will be presented at the conference.Conclusion: Our first results showed no measurable difference in the brain clearance efficacy. This could have two possible reasons. Either ventricular clearance measurements are not sensitive enough to measure AD related changes in brain clearance or the used pathogenetic model shows no changes in clearance efficacy. Our still ongoing analyses of parenchymal brain could help to elucidate further on this question.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S17)
Open AccessIntravenously administered gadolinium based contrast agent as a novel approach to longitudinally measure ventricular brain clearance with magnetic resonance imaging in an Alzheimer´s disease model
Background: Amyloidopathy, one pathological hallmark of Alzheimer’s disease (AD), results from dysbalanced amyloid‐β production and clearance. Therefore, disruptions in brain clearance may have a pivotal role as pathogenic drivers. Transgenic mice models of AD may serve to develop and establish minimally invasive in vivo measurement methods to observe brain clearance longitudinally.Method: We used magnetic resonance imaging (MRI) with intravenously administered gadolinium‐based contrast agent (GBCA) on a 7T small animal ultrahighfield MRI scanner to determine brain clearance efficacy. Imaging sessions were performed longitudinally in n = 9 APPswe/PS1dE9 (tg) mice and n = 9 wild type (wt) littermates at 6, 9 and 12 months of age with a scan protocol consisting of a highly T2w Inv. Rec. RARE (FLAIR) sequence. For a subsample of n = 6 wt and n = 6 tg at 9 and 12 months we used an additional T1w RARE sequence for evaluation of parenchymal changes. Both protocols were carried out every 5‐6.5 minutes for a total of 180 minutes. We determined mean voxel values in manually delineated volumes of interest in ventricles (in T2w images) and brain parenchyma (T1w images) using PMOD software.Result: We created intensity‐time‐curves and measured slopes for signal increase and decrease, derived from fitting with a model consisting of an exponential convoluted with another exponential and used to normalize area under the curve (AUC) values (Figure 1A‐C). Repeated measurements ANOVA revealed no differences in normalized AUC values regarding age in both lateral (p = 0.568, F(2, 28) = 0.577), 3rd (p = 0.306, F(1.903, 26.64) = 1.232) and 4th ventricles (p = 0.181, F(1.345, 18.83) = 1.924) and also no differences regarding genotype in both lateral (p = 0.684, F(1,16) = 0.172), 3rd (p = 0.737, F(1,16) = 0.117) and 4th ventricle (p = 0.186, F(1,16) = 1.910). Measurements of parenchymal clearance capacity are still ongoing and first results will be presented at the conference.Conclusion: Our first results showed no measurable difference in the brain clearance efficacy. This could have two possible reasons. Either ventricular clearance measurements are not sensitive enough to measure AD related changes in brain clearance or the used pathogenetic model shows no changes in clearance efficacy. Our still ongoing analyses of parenchymal brain could help to elucidate further on this question.
- 1 October 2023
- Published by Springer Nature
- p. 607-617
Faithful Synthesis of Low-Dose Contrast-Enhanced Brain MRI Scans Using Noise-Preserving Conditional GANs
- 1 October 2023
- Published by Springer Nature
- p. 607-617
Faithful Synthesis of Low-Dose Contrast-Enhanced Brain MRI Scans Using Noise-Preserving Conditional GANs
- Open Access
Faithful Synthesis of Low-dose Contrast-enhanced Brain MRI Scans using Noise-preserving Conditional GANs
Today Gadolinium-based contrast agents (GBCA) are indispensable in Magnetic Resonance Imaging (MRI) for diagnosing various diseases. However, GBCAs are expensive and may accumulate in patients with potential side effects, thus dose-reduction is recommended. Still, it is unclear to which extent the GBCA dose can be reduced while preserving the diagnostic value -- especially in pathological regions. To address this issue, we collected brain MRI scans at numerous non-standard GBCA dosages and developed a conditional GAN model for synthesizing corresponding images at fractional dose levels. Along with the adversarial loss, we advocate a novel content loss function based on the Wasserstein distance of locally paired patch statistics for the faithful preservation of noise. Our numerical experiments show that conditional GANs are suitable for generating images at different GBCA dose levels and can be used to augment datasets for virtual contrast models. Moreover, our model can be transferred to openly available datasets such as BraTS, where non-standard GBCA dosage images do not exist.
Open AccessFaithful Synthesis of Low-dose Contrast-enhanced Brain MRI Scans using Noise-preserving Conditional GANs
Today Gadolinium-based contrast agents (GBCA) are indispensable in Magnetic Resonance Imaging (MRI) for diagnosing various diseases. However, GBCAs are expensive and may accumulate in patients with potential side effects, thus dose-reduction is recommended. Still, it is unclear to which extent the GBCA dose can be reduced while preserving the diagnostic value -- especially in pathological regions. To address this issue, we collected brain MRI scans at numerous non-standard GBCA dosages and developed a conditional GAN model for synthesizing corresponding images at fractional dose levels. Along with the adversarial loss, we advocate a novel content loss function based on the Wasserstein distance of locally paired patch statistics for the faithful preservation of noise. Our numerical experiments show that conditional GANs are suitable for generating images at different GBCA dose levels and can be used to augment datasets for virtual contrast models. Moreover, our model can be transferred to openly available datasets such as BraTS, where non-standard GBCA dosage images do not exist.
- 22 February 2023
- Published by Wolters Kluwer Health in Investigative Radiology
- Vol. 58 (8) , 539-547
Artificial Contrast
Deep learning approaches are playing an ever-increasing role throughout diagnostic medicine, especially in neuroradiology, to solve a wide range of problems such as segmentation, synthesis of missing sequences, and image quality improvement. Of particular interest is their application in the reduction of gadolinium-based contrast agents, the administration of which has been under cautious reevaluation in recent years because of concerns about gadolinium deposition and its unclear long-term consequences. A growing number of studies are investigating the reduction (low-dose approach) or even complete substitution (zero-dose approach) of gadolinium-based contrast agents in diverse patient populations using a variety of deep learning methods. This work aims to highlight selected research and discusses the advantages and limitations of recent deep learning approaches, the challenges of assessing its output, and the progress toward clinical applicability distinguishing between the low-dose and zero-dose approach.
- 22 February 2023
- Published by Wolters Kluwer Health in Investigative Radiology
- Vol. 58 (8) , 539-547
Artificial Contrast
Deep learning approaches are playing an ever-increasing role throughout diagnostic medicine, especially in neuroradiology, to solve a wide range of problems such as segmentation, synthesis of missing sequences, and image quality improvement. Of particular interest is their application in the reduction of gadolinium-based contrast agents, the administration of which has been under cautious reevaluation in recent years because of concerns about gadolinium deposition and its unclear long-term consequences. A growing number of studies are investigating the reduction (low-dose approach) or even complete substitution (zero-dose approach) of gadolinium-based contrast agents in diverse patient populations using a variety of deep learning methods. This work aims to highlight selected research and discusses the advantages and limitations of recent deep learning approaches, the challenges of assessing its output, and the progress toward clinical applicability distinguishing between the low-dose and zero-dose approach.
- 28 January 2023
- Published by Wolters Kluwer Health in Investigative Radiology
- Vol. 58 (6) , 420-430
Reduction of Gadolinium-Based Contrast Agents in MRI Using Convolutional Neural Networks and Different Input Protocols
Objectives: The purpose of this study was to implement a state-of-the-art convolutional neural network used to synthesize artificial T1-weighted (T1w) full-dose images from corresponding noncontrast and low-dose images (using various settings of input sequences) and test its performance on a patient population acquired prospectively. Materials and Methods: In this monocentric, institutional review board–approved study, a total of 138 participants were included who received an adapted imaging protocol with acquisition of a T1w low dose after administration of 10% of the standard dose and acquisition of a T1w full dose after administration of the remaining 90% of the standard dose of a gadolinium-containing contrast agent. A total of 83 participants formed the training sample (51.7 ± 16.5 years, 36 women), 25 the validation sample (55.3 ± 16.4 years, 11 women), and 30 the test sample (55.0 ± 15.0 years, 9 women). Four input settings were differentiated: only the T1w noncontrast and T1w low-dose images (standard setting), only the T1w noncontrast and T1w low-dose images with a prolonged postinjection time of 5 minutes (5-minute setting), multiple noncontrast sequences (T1w, T2w, diffusion) and the T1w low-dose images (extended setting), and only noncontrast sequences (T1w, T2w, diffusion) were used (zero-dose setting). For each setting, a deep neural network was trained to synthesize artificial T1w full-dose images, which were assessed on the test sample using an objective evaluation based on quantitative metrics and a subjective evaluation through a reader-based study. Three readers scored the overall image quality, the interchangeability in regard to the clinical conclusion compared with the true T1w full-dose sequence, the contrast enhancement of lesions, and their conformity to the respective references in the true T1w full dose. Results: Quantitative analysis of the artificial T1w full-dose images of the standard setting provided a peak signal-to-noise ratio of 33.39 ± 0.62 (corresponding to an average improvement of the low-dose sequences of 5.2 dB) and a structural similarity index measure of 0.938 ± 0.005. In the 4-fold cross-validation, the extended setting yielded similar performance to the standard setting in terms of peak signal-to-noise ratio (P = 0.20), but a slight improvement in structural similarity index measure (P < 0.0001). For all settings, the reader study found comparable overall image quality between the original and artificial T1w full-dose images. The proportion of scans scored as fully or mostly interchangeable was 55%, 58%, 43%, and 3% and the average counts of false positives per case were 0.42 ± 0.83, 0.34 ± 0.71, 0.82 ± 1.15, and 2.00 ± 1.07 for the standard, 5-minute, extended, and zero-dose setting, respectively. Using a 5-point Likert scale (0 to 4, 0 being the worst), all settings of synthesized full-dose images showed significantly poorer contrast enhancement of lesions compared with the original full-dose sequence (difference of average degree of contrast enhancement—standard: −0.97 ± 0.83, P = P = P = P = <0.001). The average scores of conformity of the lesions compared with the original full-dose sequence were 2.25 ± 1.21, 2.22 ± 1.27, 2.24 ± 1.25, and 0.73 ± 0.93 for the standard, 5-minute, extended, and zero-dose setting, respectively. Conclusions: The tested deep learning algorithm for synthesis of artificial T1w full-dose sequences based on images after administration of only 10% of the standard dose of a gadolinium-based contrast agent showed very good quantitative performance. Despite good image quality in all settings, both false-negative and false-positive signals resulted in significantly limited interchangeability of the synthesized sequences with the original full-dose sequences.
- 28 January 2023
- Published by Wolters Kluwer Health in Investigative Radiology
- Vol. 58 (6) , 420-430
Reduction of Gadolinium-Based Contrast Agents in MRI Using Convolutional Neural Networks and Different Input Protocols
Objectives: The purpose of this study was to implement a state-of-the-art convolutional neural network used to synthesize artificial T1-weighted (T1w) full-dose images from corresponding noncontrast and low-dose images (using various settings of input sequences) and test its performance on a patient population acquired prospectively. Materials and Methods: In this monocentric, institutional review board–approved study, a total of 138 participants were included who received an adapted imaging protocol with acquisition of a T1w low dose after administration of 10% of the standard dose and acquisition of a T1w full dose after administration of the remaining 90% of the standard dose of a gadolinium-containing contrast agent. A total of 83 participants formed the training sample (51.7 ± 16.5 years, 36 women), 25 the validation sample (55.3 ± 16.4 years, 11 women), and 30 the test sample (55.0 ± 15.0 years, 9 women). Four input settings were differentiated: only the T1w noncontrast and T1w low-dose images (standard setting), only the T1w noncontrast and T1w low-dose images with a prolonged postinjection time of 5 minutes (5-minute setting), multiple noncontrast sequences (T1w, T2w, diffusion) and the T1w low-dose images (extended setting), and only noncontrast sequences (T1w, T2w, diffusion) were used (zero-dose setting). For each setting, a deep neural network was trained to synthesize artificial T1w full-dose images, which were assessed on the test sample using an objective evaluation based on quantitative metrics and a subjective evaluation through a reader-based study. Three readers scored the overall image quality, the interchangeability in regard to the clinical conclusion compared with the true T1w full-dose sequence, the contrast enhancement of lesions, and their conformity to the respective references in the true T1w full dose. Results: Quantitative analysis of the artificial T1w full-dose images of the standard setting provided a peak signal-to-noise ratio of 33.39 ± 0.62 (corresponding to an average improvement of the low-dose sequences of 5.2 dB) and a structural similarity index measure of 0.938 ± 0.005. In the 4-fold cross-validation, the extended setting yielded similar performance to the standard setting in terms of peak signal-to-noise ratio (P = 0.20), but a slight improvement in structural similarity index measure (P < 0.0001). For all settings, the reader study found comparable overall image quality between the original and artificial T1w full-dose images. The proportion of scans scored as fully or mostly interchangeable was 55%, 58%, 43%, and 3% and the average counts of false positives per case were 0.42 ± 0.83, 0.34 ± 0.71, 0.82 ± 1.15, and 2.00 ± 1.07 for the standard, 5-minute, extended, and zero-dose setting, respectively. Using a 5-point Likert scale (0 to 4, 0 being the worst), all settings of synthesized full-dose images showed significantly poorer contrast enhancement of lesions compared with the original full-dose sequence (difference of average degree of contrast enhancement—standard: −0.97 ± 0.83, P = P = P = P = <0.001). The average scores of conformity of the lesions compared with the original full-dose sequence were 2.25 ± 1.21, 2.22 ± 1.27, 2.24 ± 1.25, and 0.73 ± 0.93 for the standard, 5-minute, extended, and zero-dose setting, respectively. Conclusions: The tested deep learning algorithm for synthesis of artificial T1w full-dose sequences based on images after administration of only 10% of the standard dose of a gadolinium-based contrast agent showed very good quantitative performance. Despite good image quality in all settings, both false-negative and false-positive signals resulted in significantly limited interchangeability of the synthesized sequences with the original full-dose sequences.
- Open Access
- 7 May 2022
- Published by Springer Nature in European Radiology
- Vol. 32 (11) , 7354-7364
Anterior chamber enhancement predicts optic nerve infiltration in retinoblastoma
Objectives: As described recently, intravenously injected gadolinium-based contrast agent (GBCA) penetrates into the anterior eye chamber (AC) and is drained from the retina to the distal optic nerve (ON) along perivascular spaces, which serves retinal homeostasis and was termed the orbital glymphatic system (GS). Independently, AC enhancement predicted ON infiltration, a major risk factor for advanced retinoblastoma (RB), in a small RB patient cohort. We aimed to review the supposed imaging biomarker for ON infiltration in a large RB cohort and with respect to the recently described orbital GS. Methods: This IRB–approved retrospective single-center study encompassed 539 orbital MRIs performed with an orbital coil and with the children under general anesthesia. Differences of signal intensity ratios (∆SIRs) of the AC to the lens were determined between non-contrast and GBCA–enhanced T1-weighted images and were correlated with histopathologic presence of ON infiltration. Results: ∆SIR of the RB eye was an independent, significant predictor for ON invasion in multivariate analysis with adjustment for tumor size (p < 0.05) and increased with infiltration level. Conclusions: GBCA enhancement of the AC predicts ON infiltration. This might be caused by impairment of the orbital glymphatic system, which is supposed to clear toxic metabolites from the retina to the postlaminar ON. In RB with ON infiltration, this efflux path is likely to be inhibited, which is supposed to result in disturbed retinal homeostasis, release of vascular endothelial growth factor, and iris neovascularization, which increases penetration of GBCA into the AC. Key Points: • Infiltration of the optic nerve can be predicted by anterior chamber enhancement after intravenous MRI contrast agent administration. • Increased anterior chamber enhancement in retinoblastoma with optic nerve infiltration might result from dysfunction of the orbital glymphatic system with disturbance of retinal homeostasis and consecutive iris neovascularization.
- 7 May 2022
- Published by Springer Nature in European Radiology
- Vol. 32 (11) , 7354-7364
Open AccessAnterior chamber enhancement predicts optic nerve infiltration in retinoblastoma
Objectives: As described recently, intravenously injected gadolinium-based contrast agent (GBCA) penetrates into the anterior eye chamber (AC) and is drained from the retina to the distal optic nerve (ON) along perivascular spaces, which serves retinal homeostasis and was termed the orbital glymphatic system (GS). Independently, AC enhancement predicted ON infiltration, a major risk factor for advanced retinoblastoma (RB), in a small RB patient cohort. We aimed to review the supposed imaging biomarker for ON infiltration in a large RB cohort and with respect to the recently described orbital GS. Methods: This IRB–approved retrospective single-center study encompassed 539 orbital MRIs performed with an orbital coil and with the children under general anesthesia. Differences of signal intensity ratios (∆SIRs) of the AC to the lens were determined between non-contrast and GBCA–enhanced T1-weighted images and were correlated with histopathologic presence of ON infiltration. Results: ∆SIR of the RB eye was an independent, significant predictor for ON invasion in multivariate analysis with adjustment for tumor size (p < 0.05) and increased with infiltration level. Conclusions: GBCA enhancement of the AC predicts ON infiltration. This might be caused by impairment of the orbital glymphatic system, which is supposed to clear toxic metabolites from the retina to the postlaminar ON. In RB with ON infiltration, this efflux path is likely to be inhibited, which is supposed to result in disturbed retinal homeostasis, release of vascular endothelial growth factor, and iris neovascularization, which increases penetration of GBCA into the AC. Key Points: • Infiltration of the optic nerve can be predicted by anterior chamber enhancement after intravenous MRI contrast agent administration. • Increased anterior chamber enhancement in retinoblastoma with optic nerve infiltration might result from dysfunction of the orbital glymphatic system with disturbance of retinal homeostasis and consecutive iris neovascularization.
- 1 August 2020
- Published by Springer Nature in European Radiology
- Vol. 30 (8) , 4633-4640
The anterior eye chamber: entry of the natural excretion pathway of gadolinium contrast agents?
Objective Previous studies provided evidence that gadolinium can be found in the aqueous chamber (AC) of the eye several hours post injection (p.i.) of gadolinium-based contrast agents (GBCAs). This study aimed to investigate whether gadolinium can be detected promptly after injection of a macrocyclic GBCA on contrast-enhanced T1-weighted MRI in the AC of children. Methods This retrospective study encompassed MRI of 200 healthy eyes of children suffering from retinoblastoma of the contralateral eye. MRI was performed with an orbital coil with the children in a state of general anesthesia. Differences of signal intensity ratios ( increment SIRs) of the AC to the lens were determined between pre and post contrast-enhanced T1-weighted images (Dotarem (R), Guerbet, 0.1 ml/kg body weight, mean (standard deviation) p.i. time = 12:24 (+/- 2:31) min). Results A highly significant signal intensity increase was found in the AC of healthy eyes 12 min after GBCA injection (median increment SIR (interquartile range) = + 0.08 (0.05-0.12), p < 0.0001). In addition, gadolinium enhancement showed a strong negative correlation with children's age in multivariate analysis with adjustment for p.i. time (p < 0.0001). Conclusions GBCA leakage into the AC of healthy infantile eyes was found promptly after injection. The negative correlation between patient age and GBCA enhancement might be explained by a maturation process of the blood-aqueous barrier or Schlemm's canal. Future studies should assess the duration and potential diagnostic applications as well as possible safety concerns of gadolinium presence in the AC.
- 1 August 2020
- Published by Springer Nature in European Radiology
- Vol. 30 (8) , 4633-4640
The anterior eye chamber: entry of the natural excretion pathway of gadolinium contrast agents?
Objective Previous studies provided evidence that gadolinium can be found in the aqueous chamber (AC) of the eye several hours post injection (p.i.) of gadolinium-based contrast agents (GBCAs). This study aimed to investigate whether gadolinium can be detected promptly after injection of a macrocyclic GBCA on contrast-enhanced T1-weighted MRI in the AC of children. Methods This retrospective study encompassed MRI of 200 healthy eyes of children suffering from retinoblastoma of the contralateral eye. MRI was performed with an orbital coil with the children in a state of general anesthesia. Differences of signal intensity ratios ( increment SIRs) of the AC to the lens were determined between pre and post contrast-enhanced T1-weighted images (Dotarem (R), Guerbet, 0.1 ml/kg body weight, mean (standard deviation) p.i. time = 12:24 (+/- 2:31) min). Results A highly significant signal intensity increase was found in the AC of healthy eyes 12 min after GBCA injection (median increment SIR (interquartile range) = + 0.08 (0.05-0.12), p < 0.0001). In addition, gadolinium enhancement showed a strong negative correlation with children's age in multivariate analysis with adjustment for p.i. time (p < 0.0001). Conclusions GBCA leakage into the AC of healthy infantile eyes was found promptly after injection. The negative correlation between patient age and GBCA enhancement might be explained by a maturation process of the blood-aqueous barrier or Schlemm's canal. Future studies should assess the duration and potential diagnostic applications as well as possible safety concerns of gadolinium presence in the AC.